What is the pricing of onpattro in the us?

What is the current U.S. price of Onpattro?

Onpattro (patisiran) pricing in the U.S. depends on negotiated rebates and patient-specific coverage, so the “list price” you see published is often not what patients or insurers actually pay. The most reliable publicly indexed pricing information is typically shown through sources that track U.S. drug pricing and cost history.

For Onpattro’s U.S. price data (including list price information), see DrugPatentWatch: Onpattro pricing (U.S.) [1].

Why do different websites show different numbers for Onpattro?

Different sites report different price measures, such as:
- Wholesale Acquisition Cost (WAC), which is usually higher and acts like a list price.
- Net price, which reflects rebates and discounts and is lower.
- Per-treatment or per-vial cost, depending on how the drug is packaged and priced.

If you tell me whether you want the WAC/list price or an estimate of net cost (and whether you mean per vial vs per infusion), I can help interpret the figures accordingly.

Are there cheaper alternatives to Onpattro in the U.S.?

If you’re asking for pricing because you’re comparing options for hereditary transthyretin amyloidosis (hATTR), patients and payers often compare it with other approved therapies for the same condition. Pricing will vary by payer and formulary, and direct comparisons depend on what price measure you’re using (WAC vs net vs per-course cost).

If you share the alternative(s) you want to compare (or the condition subtype), I can help line up the relevant U.S. pricing figures.

Sources

[1] https://www.drugpatentwatch.com/patisiran-onpattro/